RECURSION PHARMACEUTICALS, INC. (RXRX) Form 8-K — Sep 21, 2026
Recursion Pharmaceuticals entered into an amendment to its Master Agreement with Tempus AI on September 15, 2026, extending the deal from five to six years and eliminating Recursion's right to terminate for convenience. The amendment cuts Recursion's annual license fees to Tempus to $14,000,000 on each of the third, fourth, and fifth anniversaries — down from the originally scheduled $42,000,000 in years three and four — with at least $4,000,000 of each payment in cash, while also reducing the volume of de-identified Tempus data Recursion may access.
Key figures
- Deal Value Usd
- $12,000,000 (non-refundable TxFM license fee payable by Tempus)
- Txfm License Term
- two years from effective date
- Master Agreement Term
- extended from five to six years from effective date
- Txfm Fee Installments
- two installments of $6,000,000 each (upon execution and at first anniversary)
- Amended Annual License Fee
- $14,000,000 on each of the third, fourth, and fifth anniversaries of the Tempus Master Agreement
- Original Annual License Fees
- ["$22,000,000 (first anniversary)","$32,000,000 (second anniversary)","$42,000,000 (each of third and fourth anniversaries)"]
- Amended Fee Minimum Cash Portion
- $4,000,000 in cash per annual payment
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.